Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line

doi:10.3748/wjg.14.5403

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4054)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

360

HTML

3299

Figures (1-6)

245

Tables (1-2)

150

Sum=4054

Sep 21, 2008 (publication date) through Jul 6, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Sep 21, 2008; 14(35): 5403-5411
Published online Sep 21, 2008. doi: 10.3748/wjg.14.5403

Full Size Figure Download Figure

Figure 1 A: Growth percentage of BxPC-3 cell line after 72 h of exposure to erlotinib at varying concentrations ranging from 1-100 μmol/L. BxPC cell proliferation was significantly suppressed by erlotinib at different concentrations; B: Growth percentage of BxPC-3 cell line after exposure to erlotinib at a concentration of 50 μmol/L at different time points.

Citation: Lu YY, Jing DD, Xu M, Wu K, Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol 2008; 14(35): 5403-5411
URL: https://www.wjgnet.com/1007-9327/full/v14/i35/5403.htm
DOI: https://dx.doi.org/10.3748/wjg.14.5403